tiprankstipranks
Trending News
More News >
InnoCare Pharma Ltd. (HK:9969)
:9969
Hong Kong Market
Advertisement

InnoCare Pharma Ltd. (9969) Stock Forecast & Price Target

Compare
1 Followers
See the Price Targets and Ratings of:

9969 Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
InnoCare
Pharma Ltd.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

9969 Stock 12 Month Forecast

Average Price Target

HK$18.52
▲(4.16%Upside)
Based on 3 Wall Street analysts offering 12 month price targets for InnoCare Pharma Ltd. in the last 3 months. The average price target is HK$18.52 with a high forecast of HK$25.20 and a low forecast of HK$11.95. The average price target represents a 4.16% change from the last price of HK$17.78.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"HK$3","26":"HK$26","8.75":"HK$8.75","14.5":"HK$14.5","20.25":"HK$20.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$25.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$18.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$11.95</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,8.75,14.5,20.25,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2023","6":"Sep<br/>2024","9":"Feb<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.1,14.03076923076923,14.961538461538462,15.892307692307693,16.823076923076922,17.753846153846155,18.684615384615384,19.615384615384613,20.546153846153846,21.47692307692308,22.407692307692308,23.338461538461537,24.269230769230766,{"y":25.2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.1,13.516923076923076,13.933846153846153,14.350769230769231,14.767692307692307,15.184615384615384,15.60153846153846,16.018461538461537,16.435384615384613,16.85230769230769,17.269230769230766,17.686153846153847,18.103076923076923,{"y":18.52,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.1,13.01153846153846,12.923076923076923,12.834615384615384,12.746153846153845,12.657692307692308,12.569230769230769,12.48076923076923,12.392307692307691,12.303846153846154,12.215384615384615,12.126923076923076,12.038461538461538,{"y":11.95,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.54,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.54,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.54,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$25.20Average Price TargetHK$18.52Lowest Price TargetHK$11.95
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on HK:9969
TipRanks AITipRanks
Not Ranked
TipRanks
HK$19
Hold
6.86%
Upside
Reiterated
07/17/25
InnoCare Pharma Ltd.'s stock score is driven by strong technical analysis indicators, suggesting positive momentum, despite significant financial performance challenges. The lack of profitability and cash flow issues weigh heavily, but the bullish market trends provide some optimism.
Goldman Sachs Analyst forecast on HK:9969
Ziyi ChenGoldman Sachs
Goldman Sachs
HK$12.72HK$18.41
Buy
3.54%
Upside
Reiterated
07/09/25
Goldman Sachs Sticks to Its Buy Rating for InnoCare Pharma Ltd. (9969)
CMB International Securities Analyst forecast on HK:9969
Jill WuCMB International Securities
CMB International Securities
HK$11.95
Buy
-32.79%
Downside
Reiterated
05/15/25
InnoCare Pharma Ltd.: Strong Financial Performance and Promising Pipeline Drive Buy Rating
Jefferies Analyst forecast on HK:9969
Chris LuiJefferies
Jefferies
HK$12HK$8.8
Buy
-50.51%
Downside
Reiterated
10/25/24
Jefferies Sticks to Its Buy Rating for InnoCare Pharma Ltd. (9969)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on HK:9969
TipRanks AITipRanks
Not Ranked
TipRanks
HK$19
Hold
6.86%
Upside
Reiterated
07/17/25
InnoCare Pharma Ltd.'s stock score is driven by strong technical analysis indicators, suggesting positive momentum, despite significant financial performance challenges. The lack of profitability and cash flow issues weigh heavily, but the bullish market trends provide some optimism.
Goldman Sachs Analyst forecast on HK:9969
Ziyi ChenGoldman Sachs
Goldman Sachs
HK$12.72HK$18.41
Buy
3.54%
Upside
Reiterated
07/09/25
Goldman Sachs Sticks to Its Buy Rating for InnoCare Pharma Ltd. (9969)
CMB International Securities Analyst forecast on HK:9969
Jill WuCMB International Securities
CMB International Securities
HK$11.95
Buy
-32.79%
Downside
Reiterated
05/15/25
InnoCare Pharma Ltd.: Strong Financial Performance and Promising Pipeline Drive Buy Rating
Jefferies Analyst forecast on HK:9969
Chris LuiJefferies
Jefferies
HK$12HK$8.8
Buy
-50.51%
Downside
Reiterated
10/25/24
Jefferies Sticks to Its Buy Rating for InnoCare Pharma Ltd. (9969)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering InnoCare Pharma Ltd.

1 Month
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+39.53%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +39.53% per trade.
3 Months
xxx
Success Rate
2/3 ratings generated profit
67%
Average Return
+57.50%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +57.50% per trade.
1 Year
Chris LuiJefferies
Success Rate
2/3 ratings generated profit
67%
Average Return
+120.87%
reiterated a buy rating 9 months ago
Copying Chris Lui's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +120.87% per trade.
2 Years
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+160.57%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +160.57% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9969 Analyst Recommendation Trends

Rating
Jan 25
Feb 25
May 25
Jun 25
Jul 25
Strong Buy
1
1
1
1
0
Buy
2
2
2
1
2
Hold
0
0
0
3
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
3
3
5
8
In the current month, 9969 has received 2 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. 9969 average Analyst price target in the past 3 months is 18.52.
Each month's total comprises the sum of three months' worth of ratings.

9969 Financial Forecast

9969 Earnings Forecast

Next quarter’s earnings estimate for 9969 is -HK$0.10 with a range of -HK$0.10 to -HK$0.10. The previous quarter’s EPS was HK$0.01. 9969 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.43% of the time in the same period. In the last calendar year 9969 has Outperformed its overall industry.
Next quarter’s earnings estimate for 9969 is -HK$0.10 with a range of -HK$0.10 to -HK$0.10. The previous quarter’s EPS was HK$0.01. 9969 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.43% of the time in the same period. In the last calendar year 9969 has Outperformed its overall industry.

9969 Sales Forecast

Next quarter’s sales forecast for 9969 is HK$791.12M with a range of HK$791.12M to HK$791.12M. The previous quarter’s sales results were ―. 9969 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 49.11% of the time in the same period. In the last calendar year 9969 has Preformed in-line its overall industry.
Next quarter’s sales forecast for 9969 is HK$791.12M with a range of HK$791.12M to HK$791.12M. The previous quarter’s sales results were ―. 9969 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 49.11% of the time in the same period. In the last calendar year 9969 has Preformed in-line its overall industry.

9969 Stock Forecast FAQ

What is HK:9969’s average 12-month price target, according to analysts?
Based on analyst ratings, InnoCare Pharma Ltd.’s 12-month average price target is 18.52.
    What is HK:9969’s upside potential, based on the analysts’ average price target?
    InnoCare Pharma Ltd. has 4.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is InnoCare Pharma Ltd. a Buy, Sell or Hold?
          InnoCare Pharma Ltd. has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
            What is InnoCare Pharma Ltd.’s share price target?
            The average share price target for InnoCare Pharma Ltd. is 18.52. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$25.20 ,and the lowest forecast is HK$11.95. The average share price target represents 4.16% Increase from the current price of HK$17.78.
              What do analysts say about InnoCare Pharma Ltd.?
              InnoCare Pharma Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of InnoCare Pharma Ltd.?
                To buy shares of HK:9969, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis